abraxane,paclitaxel
amgen
['sequence,(-consequence)']
dr. carrato presents the sequence trial, gem/nab-p followed by folfox vs gem/nab-p for pdac. pfs 7.9 vs 5.2 months (hr 0.51) and os 13.2 vs 9.7 months (hr 0.676). 12m os rate (primary endpoint) 55.3 vs 35.4%. #asco22 
Gastrointestinal medical oncology, cancer of unknown primary, and value-based cancer care delivery. Tweets mine.